Genmab Partners With Immatics To Discover and Develop Next-Generation Immunotherapies
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 7 (Table of Contents)
Published: 27 Jul-2018
DOI: 10.3833/pdr.v2018.i7.2339 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Seeking to develop new bispecific immunotherapies, Genmab has gained exclusive access to multiple proprietary targets from Immatics Biotechnologies (Immatics), identified by the latter’s Xpresident® and T cell receptor technology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS